Pharmacogenomics of responsiveness to interferon IFN-β treatment in multiple sclerosis:: A genetic screen of 100 type I interferon-inducible genes

被引:57
作者
Cunningham, S
Graham, C
Hutchinson, M
Droogan, A
O'Rourke, L
Patterson, C
McDonnell, G
Hawkins, S
Vandenbroeck, K
机构
[1] Queens Univ Belfast, Sch Pharm, McClay Ctr Pharmaceut Sci, Chair Appl Genom,Appl Genom Res Grp, Belfast BT9 7BL, Antrim, North Ireland
[2] Belfast City Hosp, Ctr Med Genet, Belfast BT9 7AD, Antrim, North Ireland
[3] St Vincents Univ Hosp, Dept Neurol, Dublin, Ireland
[4] Univ Coll Dublin, Dublin 2, Ireland
[5] Royal Victoria Hosp, Dept Neurol, Belfast BT12 6BA, Antrim, North Ireland
[6] Queens Univ Belfast, Sch Med, Dept Epidemiol & Publ Hlth, Belfast, Antrim, North Ireland
[7] Queens Univ Belfast, Sch Med, Belfast, Antrim, North Ireland
关键词
D O I
10.1016/j.clpt.2005.08.018
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives. Interferon IFN-beta is indicated for the treatment of multiple sclerosis. A significant proportion of patients show a poor clinical response to therapy. Type I interferon exerts its effect at least partially through interaction of specific transcription factors with interferon-stimulated response elements (ISREs), mostly located in promoter regions of its target genes. We hypothesized that polymorphisms may occur within or dose to ISRE elements, altering type I interferon inducibility and ultimately leading to a modified clinical response in carriers. Methods: We selected 100 ISRE-containing genes and sequenced their promoter regions in small genomic deoxyribonucleic acid pools of responding and nonresponding patients, as well as healthy control subjects. A selection of polymorphisms discovered by this approach was scrutinized subsequently in a collection of individual deoxyribonucleic acid samples. Results. We identified 4 genes containing polymorphisms associated with response to recombinant IFN-beta: IFNAR1 (P = .036), LMP7 (P = .002; odds ratio [OR], 6.37 [95% confidence interval (CI), 1.84-24.1]), CTSS (P = .02; 01, 0.38 [95% CI, 0.18-0.84]), and MxA (P = .015; OR, 3.37 [95% CI, 1.11-11.4]). Logistic regression analysis with treatment outcome used as the dependent variable and genotype as the independent variable revealed 2 genes, LMP7(OR, 0.55 [95% CI, 0.34-0.89]) and MxA (OF, 0.41 [95% CI, 0.19-0.88]), that were independently associated with treatment response. Conclusions. Our work confirms and extends previous indications for a polygenic mechanism involved in bringing about responsiveness to recombinant IFN-beta. The identification of 2 genes active in the antigen processing and presentation cascade; that is, LMP7, coding for the proteasome subunit R, and CTSS, coding for cathepsin S; as potential response modifiers may identify this pathway as being of particular relevance to phenotypic expression of response heterogeneity.
引用
收藏
页码:635 / 646
页数:12
相关论文
共 55 条
[1]   Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-β1a [J].
Antonelli, G ;
Bagnato, F ;
Pozzilli, C ;
Simeoni, E ;
Bastianelli, S ;
Currenti, M ;
De Pisa, F ;
Fieschi, C ;
Gasperini, C ;
Salvetti, M ;
Dianzani, F .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1998, 18 (05) :345-350
[2]  
Antonelli G, 1999, EUR CYTOKINE NETW, V10, P413
[3]   Association testing by DNA pooling: An effective initial screen [J].
Bansal, A ;
van den Boom, D ;
Kammerer, S ;
Honisch, C ;
Adam, G ;
Cantor, CR ;
Kleyn, P ;
Braun, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (26) :16871-16874
[4]  
Beck H, 2001, EUR J IMMUNOL, V31, P3726, DOI 10.1002/1521-4141(200112)31:12<3726::AID-IMMU3726>3.0.CO
[5]  
2-O
[6]   THE INTERFERON-STIMULATED GENE 54 K PROMOTER CONTAINS 2 ADJACENT FUNCTIONAL INTERFERON-STIMULATED RESPONSE ELEMENTS OF DIFFERENT STRENGTH, WHICH ACT SYNERGISTICALLY FOR MAXIMAL INTERFERON-ALPHA INDUCIBILITY [J].
BLUYSSEN, HAR ;
VLIETSTRA, RJ ;
VANDERMADE, A ;
TRAPMAN, J .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1994, 220 (02) :395-402
[7]   Determining SNP allele frequencies in DNA pools [J].
Breen, G ;
Harold, D ;
Ralston, S ;
Shaw, D ;
Clair, DS .
BIOTECHNIQUES, 2000, 28 (03) :464-+
[8]   Mechanisms of immune injury in multiple sclerosis [J].
Brosnan, CF ;
Raine, CS .
BRAIN PATHOLOGY, 1996, 6 (03) :243-257
[9]   Genomic control for association studies [J].
Devlin, B ;
Roeder, K .
BIOMETRICS, 1999, 55 (04) :997-1004
[10]   Cathepsin S controls the trafficking and maturation of MHC class II molecules in dendritic cells [J].
Driessen, C ;
Bryant, RAR ;
Lennon-Duménil, AM ;
Villadangos, JA ;
Bryant, PW ;
Shi, GP ;
Chapman, HA ;
Ploegh, HL .
JOURNAL OF CELL BIOLOGY, 1999, 147 (04) :775-790